Reframe vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W21 alcohol reduction app at $13M ARR with 150K+ paying customers; $17.4M Series B Goodwater 2022 with neuroscience-based CBT and community support competing with Monument for gray-area drinker digital behavior change.
About
Reframe (formerly Glucobit) is a San Francisco-based digital health platform — backed by Y Combinator (W21) — providing people seeking to quit or reduce alcohol consumption with a neuroscience-based mobile app that combines behavioral psychology, habit tracking, and community support, achieving $13 million in annual revenue with 150,000+ paying customers after 10x growth in 12 months and 3,000% growth in 6 months to become one of the top health apps on the App Store. Founded in 2018 by Ziyi Gao and Vedant Pradeep, Reframe raised $17.4 million in a Series B in January 2022 from Goodwater Capital, applying evidence-based alcohol reduction techniques (including CBT, mindfulness, and neuroscience education about alcohol's brain effects) to the 30 million Americans who want to drink less but don't seek traditional addiction treatment.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.